- Home
- BDSX vs NLSP Comparison
BDSX vs NLSP Comparison
Compare BDSX & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDSX
- NLSP
- Stock Information
- Founded
- BDSX 2005
- NLSP 2015
- Country
- BDSX United States
- NLSP Switzerland
- Employees
- BDSX N/A
- NLSP N/A
- Industry
- BDSX Precision Instruments
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- BDSX Health Care
- NLSP Health Care
- Exchange
- BDSX Nasdaq
- NLSP Nasdaq
- Market Cap
- BDSX 115.4M
- NLSP 12.4M
- IPO Year
- BDSX 2020
- NLSP 2021
- Fundamental
- Price
- BDSX $0.32
- NLSP $2.24
- Analyst Decision
- BDSX Strong Buy
- NLSP
- Analyst Count
- BDSX 5
- NLSP 0
- Target Price
- BDSX $1.75
- NLSP N/A
- AVG Volume (30 Days)
- BDSX 846.2K
- NLSP 308.9K
- Earning Date
- BDSX 08-06-2025
- NLSP 07-29-2025
- Dividend Yield
- BDSX N/A
- NLSP N/A
- EPS Growth
- BDSX N/A
- NLSP N/A
- EPS
- BDSX N/A
- NLSP N/A
- Revenue
- BDSX $74,463,000.00
- NLSP N/A
- Revenue This Year
- BDSX $17.29
- NLSP N/A
- Revenue Next Year
- BDSX $29.33
- NLSP N/A
- P/E Ratio
- BDSX N/A
- NLSP N/A
- Revenue Growth
- BDSX 35.76
- NLSP N/A
- 52 Week Low
- BDSX $0.17
- NLSP $1.30
- 52 Week High
- BDSX $2.04
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- BDSX 54.89
- NLSP 46.57
- Support Level
- BDSX $0.29
- NLSP $2.06
- Resistance Level
- BDSX $0.32
- NLSP $2.35
- Average True Range (ATR)
- BDSX 0.02
- NLSP 0.22
- MACD
- BDSX 0.01
- NLSP -0.04
- Stochastic Oscillator
- BDSX 95.65
- NLSP 14.33
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.